Detomidine Hydrochloride

Alpha-2 Adrenergic Agonist Sedative, Analgesic, Muscle Relaxant

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Horse IV 0.01-0.02 mg/kg for mild sedation; 0.02-0.04 mg/kg for deep sedation/analgesia Single dose; may repeat at 30-60 min if needed Duration: 30-60 min for sedation; up to 90 min for analgesia
Notes: Administer slowly IV. For colic pain, use 0.01-0.02 mg/kg IV. Avoid in horses with cardiac disease.
Horse IM 0.02-0.04 mg/kg Single dose Duration: 30-60 min
Notes: Onset of action is slower (5-10 min) compared to IV.
Cattle IV or IM 0.02-0.04 mg/kg Single dose Duration: 30-60 min
Notes: Use with caution in pregnant animals. May cause recumbency at higher doses.
Dog IV or IM 0.01-0.04 mg/kg Single dose Duration: 30-60 min
Notes: Often used in combination with opioids (e.g., butorphanol) for neuroleptanalgesia.
Cat IV or IM 0.01-0.04 mg/kg Single dose Duration: 30-60 min
Notes: Use with caution in cats with hepatic or renal disease.
Small Ruminants (sheep, goats) IV or IM 0.02-0.04 mg/kg Single dose Duration: 30-60 min
Notes: May cause bloat due to rumen stasis; monitor closely.
Rabbit IM 0.05-0.1 mg/kg Single dose Duration: 30-60 min
Notes: Use with caution; rabbits are sensitive to alpha-2 agonists.
Bird/Poultry IM 0.02-0.1 mg/kg (species-specific) Single dose Duration: Variable
Notes: Limited data; use with caution and monitor respiratory function.

Clinical Indications & Species Uses

General Indications
  • Sedation
  • Analgesia
  • Muscle relaxation
  • Preanesthetic medication
Dog (Canine)
  • Sedation
  • Analgesia
  • Preanesthetic medication
Cat (Feline)
  • Sedation
  • Analgesia
  • Preanesthetic medication
Horse (Equine)
  • Sedation
  • Analgesia
  • Preanesthetic medication
  • Standing restraint for minor surgical procedures
  • Treatment of colic pain
Cattle (Bovine)
  • Sedation
  • Analgesia
  • Preanesthetic medication
  • Standing restraint for minor surgical procedures
Small Ruminants (Sheep / Goat)
  • Sedation
  • Analgesia
  • Preanesthetic medication
Rabbit & Small Mammals
  • Sedation
  • Analgesia
Avian & Poultry
  • Sedation
  • Analgesia (limited use)
Exotic & Other Species
  • Sedation and analgesia in various exotic species (e.g., reptiles, wildlife) at species-specific doses

Pharmacology & Mechanism of Action

Drug Class: Alpha-2 Adrenergic Agonist | Pharmacological Group: Sedative, Analgesic, Muscle Relaxant

Mechanism of Action: Detomidine is a potent and selective alpha-2 adrenergic agonist. It exerts its effects by binding to and activating alpha-2 adrenergic receptors in the central nervous system (CNS), particularly in the locus coeruleus and other brainstem areas. This activation leads to a decrease in sympathetic outflow, resulting in sedation, analgesia, and muscle relaxation. The analgesic effect is mediated both centrally and peripherally via alpha-2 receptors in the spinal cord and peripheral tissues. Detomidine also inhibits the release of norepinephrine, further contributing to its sedative and hypotensive effects.

Pharmacodynamics: Detomidine produces dose-dependent sedation, analgesia, and muscle relaxation. At low doses, it causes mild sedation and analgesia; at higher doses, deep sedation and profound analgesia occur. It also induces bradycardia, initially hypertension followed by hypotension, and decreased cardiac output. Respiratory rate may decrease, but arterial blood gases typically remain within normal limits in healthy animals. Detomidine also has effects on the gastrointestinal tract, including reduced motility and increased gastric tone. In horses, it can cause ataxia and penile prolapse. The duration of action is dose-dependent, with effects lasting from 30 minutes to over an hour.

⚡ Pharmacokinetics Summary

Absorption: Detomidine is well absorbed after intramuscular (IM) injection, with peak plasma concentrations occurring within 15-30 minutes. After oral administration, absorption is rapid but undergoes extensive first-pass metabolism, resulting in low bioavailability. In horses, oral bioavailability is approximately 22%.
Distribution: Detomidine is widely distributed throughout the body. It crosses the blood-brain barrier to exert its central effects. The volume of distribution is large, indicating extensive tissue binding. Protein binding is approximately 90% in horses.
Metabolism: Detomidine is extensively metabolized in the liver, primarily by hydroxylation and conjugation (glucuronidation and sulfation). The major metabolites are inactive. In horses, the primary metabolite is 3-hydroxy-detomidine, which is excreted in urine and feces.
Excretion: Detomidine and its metabolites are excreted primarily in urine (about 60%) and feces (about 30%). In horses, the elimination half-life is approximately 1-2 hours after IV administration, but the pharmacodynamic effects may last longer than the plasma half-life.
Half-Life: Horse: ~1-2 hours (IV); Cattle: ~1 hour; Dog: ~0.5-1 hour (IV)
Bioavailability: IM: ~100% (horses); Oral: ~22% (horses)
Protein Binding: Approximately 90% in horses

Available Formulations & Strengths

Injectable Solution 10 mg/mL (1% solution) (IV or IM)
Oral Gel 7.6 mg/mL (for horses) (Oral)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to detomidine or other alpha-2 agonists
  • Severe cardiac disease, arrhythmias, or hypotension
  • Respiratory distress or severe respiratory disease
  • Shock or severe debilitation
  • Hepatic or renal insufficiency (use with caution)
  • Pregnancy (especially late-term) unless benefits outweigh risks
  • Concurrent use of other sedatives or anesthetics without dose adjustment
Warnings & Clinical Precautions:
  • Use with caution in animals with pre-existing cardiovascular disease, as bradycardia and hypotension may occur.
  • Monitor heart rate, respiratory rate, and blood pressure during use.
  • In horses, detomidine can cause ataxia; ensure a safe environment to prevent injury.
  • May cause penile prolapse in male horses; monitor and protect the penis.
  • In ruminants, may cause rumen stasis and bloat; monitor for signs of bloat.
  • Use with caution in very young, old, or debilitated animals.
  • Have reversal agents (e.g., yohimbine, atipamezole) available.
  • Avoid extra-label use in food animals without observing withdrawal times.
  • In cats, may cause vomiting; use with caution.
  • Do not use in animals with a history of seizures.

Adverse Effects & Reactions

Common:

  • Bradycardia
  • Hypotension (after initial transient hypertension)
  • Ataxia (especially in horses)
  • Muscle tremors
  • Sweating (in horses)
  • Penile prolapse (in male horses)
  • Reduced gastrointestinal motility
  • Mild respiratory depression
  • Vomiting (in cats and dogs)

Serious / Severe:

  • Severe hypotension or cardiovascular collapse
  • Arrhythmias (e.g., AV block)
  • Respiratory arrest
  • Prolonged sedation or recovery
  • Hyperglycemia (transient)
  • Rumen tympany in ruminants

Rare:

  • Paradoxical excitation
  • Allergic reactions (e.g., urticaria, anaphylaxis)
  • Hepatic or renal toxicity (with overdose)
  • Seizures (in predisposed animals)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other CNS depressants (e.g., barbiturates, anesthetics, opioids) Additive sedative and respiratory depressant effects; reduce doses of both drugs. High
Anticholinergics (e.g., atropine) May reduce bradycardia but can cause hypertension and tachycardia; use with caution. Moderate
Sympathomimetic amines (e.g., epinephrine) May cause severe hypertension and arrhythmias due to unopposed alpha-1 stimulation. High
Beta-blockers (e.g., propranolol) May exacerbate bradycardia and hypotension. Moderate
Tricyclic antidepressants (e.g., amitriptyline) May potentiate cardiovascular effects. Moderate
Yohimbine or atipamezole (alpha-2 antagonists) Reversal of detomidine effects; use to manage overdose or to hasten recovery. Mild (therapeutic)

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe bradycardia
  • Hypotension or hypertension
  • Respiratory depression
  • Deep sedation or unconsciousness
  • Ataxia or recumbency
  • Muscle tremors
  • Hypothermia
  • Cardiovascular collapse

Emergency Treatment Protocol: Treatment of detomidine overdose is primarily supportive. Administer alpha-2 antagonists such as yohimbine (0.1-0.2 mg/kg IV in horses; 0.1 mg/kg IV in dogs) or atipamezole (0.05-0.1 mg/kg IV in horses; 0.05-0.1 mg/kg IV in dogs) to reverse effects. Provide respiratory support (oxygen, ventilation) if needed. Monitor cardiovascular parameters and treat arrhythmias if they occur. Maintain body temperature and provide a quiet, warm environment. In severe cases, intravenous fluids may be administered to support blood pressure.

Food Animal Withdrawal Times

🥩 Meat: 3 days🥛 Milk: 3 days

Withdrawal times are for horses and cattle in the US. For other species and countries, consult local regulations. In the US, detomidine is not approved for use in food animals, but extra-label use requires extended withdrawal times (e.g., 5-7 days for meat and 5 days for milk) as per FARAD recommendations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), with excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Protect from freezing. Keep container tightly closed. Store away from direct sunlight.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in horses and cattle in the US (e.g., Dormosedan).

Extra-Label (Off-Label) Use: In the US, detomidine is approved for use in horses and cattle. Extra-label use in other species or for other indications is permitted under AMDUCA (Animal Medicinal Drug Use Clarification Act) provided there is a valid veterinarian-client-patient relationship, and withdrawal times are extended as recommended by FARAD.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Detomidine is a valuable alpha-2 agonist for sedation and analgesia in veterinary practice, particularly in horses and cattle. It provides reliable, reversible sedation with minimal cardiopulmonary depression when used at appropriate doses. However, its cardiovascular effects (bradycardia, transient hypertension, then hypotension) require careful monitoring, especially in compromised animals. Reversal agents (yohimbine, atipamezole) should be readily available. In food animals, strict adherence to withdrawal times is essential. Detomidine is often combined with opioids (e.g., butorphanol) for enhanced analgesia and sedation. It is important to adjust doses in young, old, or debilitated animals and to avoid use in animals with significant cardiac or respiratory disease. Always follow label directions and consult current veterinary references for specific dosing and safety information.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)